Harbor Investment Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Harbor Investment Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$70.4K	Buy	292 +227	+349%	+$49.7K	﹤0.01%	659
2026 Q1	$12.3K	Hold	65	–	–	﹤0.01%	875
2025 Q4	$11.1K	Buy	+65	New	+$9.96K	﹤0.01%	919
2024 Q3	–	Sell	-1	Closed	-$107	–	1231
2024 Q2	$107	Buy	+1	New	+$110	﹤0.01%	1253
2022 Q1	–	Sell	-75	Closed	-$10K	–	1360
2021 Q4	$10K	Sell	75 -4,748	-98%	-$624K	﹤0.01%	1054
2021 Q3	$628K	Buy	4,823 +1,704	+55%	+$257K	0.09%	192
2021 Q2	$554K	Buy	+3,119	New	+$540K	0.08%	217

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Harbor Investment Advisory's JAZZ Position: Q2 2026 in Review

Harbor Investment Advisory increased its Jazz Pharmaceuticals (JAZZ) stake by 349% in Q2 2026, buying an estimated $49.7K and bringing the position to 292 shares worth $70.4K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

Harbor Investment Advisory first reported a position in JAZZ in Q2 2021 and has held it in 7 quarters since. The position peaked at $628K in Q3 2021. 303 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Harbor Investment Advisory held 292 shares of Jazz Pharmaceuticals worth $70.4K as of Q2 2026.
Harbor Investment Advisory bought 227 Jazz Pharmaceuticals shares in Q2 2026, an estimated $49.7K.
Jazz Pharmaceuticals made up ﹤0.01% of Harbor Investment Advisory's portfolio in Q2 2026, its #659 holding.
Harbor Investment Advisory first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 7 quarters since.
Harbor Investment Advisory's Jazz Pharmaceuticals position peaked at $628K in Q3 2021.
303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Harbor Investment Advisory's 13F filing for Q2 2026, filed 7 Jul 2026.